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Purpose: The increasing prevalence of antimicrobial resistant bacteria has become 
a serious worldwide problem. The aim of this study was to analyze antimicrobial 
resistance data generated in 2009 by hospitals and commercial laboratories partici-
pating in the Korean Nationwide Surveillance of Antimicrobial Resistance pro-
gram. Materials and Methods: Susceptibility data were collected from 24 hospi-
tals and two commercial laboratories. In the analysis, resistance did not include 
intermediate susceptibility. Duplicate isolates were excluded from the analysis of 
hospital isolates, but not from the commercial laboratory isolates. Results: Among 
the hospital isolates, methicillin-resistant Staphylococcus aureus, penicillin G-non-
susceptible Streptococcus pneumoniae based on meningitis breakpoint, and ampi-
cillin-resistant Enterococcus faecium remained highly prevalent. The proportion of 
vancomycin-resistant E. faecium gradually increased to 29%. Ceftazidime-resistant 
Escherichia coli and Klebsiella pneumoniae increased to 17% and 33%, respective-
ly, and fluoroquinolone-resistant K. pneumoniae, Acinetobacter spp. and Pseudo-
monas aeruginosa increased to 33%, 67% and 39%, respectively. Amikacin-resis-
tant Acinetobacter spp. increased to 48%. Imipenem-resistant Acinetobacter spp. 
and P. aeruginosa increased to 51% and 26%, respectively. Higher resistance rates 
were observed in intensive care unit (ICU) isolates than in non-ICU isolates among 
the isolates from hospitals. Resistance rates were higher in hospital isolates than in 
clinic isolates among the isolates from commercial laboratories. Conclusion: 
Among the hospital isolates, ceftazidime-resistant K. pneumoniae and fluoroquino-
lone-resistant K. pneumoniae, Acinetobacter spp., and P. aeruginosa further in-
creased. The increase in imipenem resistance was slight in P. aeruginosa, but dras-
tic in Acinetobacter spp. The problematic antimicrobial-organism combinations 
were much more prevalent among ICU isolates.
Key Words:   Antimicrobial resistance surveillance, fluoroquinolone resistance, 
imipenem resistance, KONSAR, Staphylococcus, Acinetobacter 
spp., P. aeruginosa
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resistant Enterococcus faecium and imipenem-resistant Aci-
netobacter spp., was also found. In addition, third-generation 
cephalosporin-resistant E. coli and K. pneumoniae, and imi-
penem-resistant P. aeruginosa were highly prevalent among 
the commercial laboratory (Com Lab) tested isolates.
In the present study, the trends of resistance of the afore-
mentioned antimicrobial-organism combinations were de-
termined. Stenotrophomonas maltophilia was also added to 
the surveillance study, because this organism is naturally re-
sistant to quite a few classes of antimicrobial agents, and 
because it has been increasingly detected. Because inten-
sive care units (ICUs) are a major source of resistant bacte-
ria, resistance rates of isolates from ICUs and non-ICUs 
were compared using the data generated at six large hospi-
tals with >1,000 beds. Resistance rates of isolates from sec-
ondary-care hospitals and from primary care clinics were 
also compared using data from a Com Lab.
MATERIALS AND METHODS
Antimicrobial susceptibility data were generated in 2009 
from participating KONSAR hospitals and two Com Labs. 
Among the data collected, those from 24 hospitals were an-
alyzed, excluding hospitals with poor quality performance. 
Two Com Labs processed specimens requested by institu-
tions with no in-house microbiology laboratory, i.e. second-
ary care hospitals and primary-care clinics. 
Responses to a questionnaire revealed that methods of sus-
ceptibility testing used by the participants were: for E. coli 
(representing Gram-negative bacilli), the CLSI disk diffu-
sion12 in two laboratories, the commercial broth microdilu-
tion methods in 19, and both methods in three; for S. aureus 
(representing Gram-positive cocci), the CLSI disk diffusion 
in three laboratories, the broth microdilution method in 17, 
and both methods in four. Fluoroquinolone susceptibility was 
tested using either ciprofloxacin or levofloxacin. Cefotaxime 
and ceftazidime susceptibility was interpreted according to 
the previous CLSI breakpoints.12 For all Streptococcus pneu-
moniae isolates, the oxacillin disk test was used to screen 
penicillin nonsusceptible isolates for meningitis interpreta-
tion, because the majority of the serotypes in the respiratory 
tract can cause meningitis. The MIC of penicillin G was used 
to determine meningitis breakpoint-based susceptibility.13
The majority of the laboratories used WHONET soft-
ware14 to analyze routine test data. Duplicate isolates were 
excluded from the analysis of hospital isolates, but not from 
INTRODUCTION
The increasing prevalence of antimicrobial resistant bacte-
ria has become a serious worldwide problem. The preva-
lence of antibiotic-resistant bacteria varies greatly from 
country to country, because it is greatly influenced by anti-
microbial usage and failure to control the spread of resistant 
bacteria. Antimicrobial-resistant bacteria have been rela-
tively more prevalent in Asian countries1 and in some Euro-
pean countries such as Spain, Italy and France (www.ecdc.
europa.eu). Although bacterial resistance has generally 
been rare in Scandinavian countries, rare antimicrobial-or-
ganism combinations are being reported with increasing 
frequency, mostly due to importation from other countries.2
In general, resistant bacteria have been less prevalent in the 
U.S. and in Europe; however, vancomycin-resistant entero-
cocci were first reported in the U.K. and France in 1988.3,4 
Following the first discovery of highly vancomycin-resis-
tant VanA-producing Staphylococcus aureus in the U.S., 
nine more isolates were subsequently detected, while only 
one of each was isolated in India and Iran.5 The KPC type 
carbapenemase-producing Klebsiella pneumoniae emerged 
in the U.S.6 and spread to other countries. 
Resistance of Gram-positive cocci was once considered to 
be a more serious problem, but the emergence of carbapen-
em-resistant Gram-negative bacilli, either due to class A β- 
lactamase, KPC,6 or class B β-lactamases, IMP, VIM, recent-
ly identified NDM-1, etc.7,8 raised great concern once again 
about the resistance of Gram-negative bacilli, because these 
enzymes can inactivate the most potent class of β-lactam an-
tibiotics, i.e. carbapenems. 
An antimicrobial resistance surveillance study is a funda-
mental means of appreciating trends in resistance, develop-
ing accurate treatment guidelines, and evaluating the efficacy 
of intervention (www.who.int/drugresistance/en/). Monitor-
ing the temporal trend of resistance is an essential element 
of the detection of subtle variations in antimicrobial resis-
tance.9 The Korean Nationwide Surveillance of Antimicro-
bial Resistance (KONSAR) program has been conducted 
for the purpose of surveillance since 1997.10 The study from 
200711 showed continued prevalence of methicillin-resis-
tant S. aureus (MRSA), third-generation cephalosporin-re-
sistant K. pneumoniae, and fluoroquinolone-resistant Esch-
erichia coli, Pseudomonas aeruginosa and Acinetobacter 
spp. A high amikacin resistance rate in Acinetobacter spp., 
and, more importantly, a gradual increase in vancomycin-
KONSAR Study in 2009
Yonsei Med J   http://www.eymj.org   Volume 52   Number 5   September 2011 795
Antimicrobial resistance 
The antimicrobial resistance rates of Gram-negative bacilli 
isolated in 2009 are shown in Table 2. The resistance rates 
of hospital-tested E. coli isolates were 67% to ampicillin, 
19% to cefotaxime, 4% to piperacillin-tazobactam, 2% to 
amikacin, 35% to fluoroquinolone, and 36% to cotrimoxa-
zole. The resistance rates of the Com Lab-tested E. coli iso-
lates were slightly higher than those of the hospital isolates. 
The cefoxitin resistance rates of the hospital and Com Lab 
isolates were 8% and 15%, respectively. The resistance 
rates of hospital-isolated K. pneumoniae were 33% to cef-
tazaidime, 15% to piperacillin-tazobactam, 25% to cefoxi-
tin, 15% to amikacin, and 33% to fluoroquinolone. The ES-
BL-positive rates of hospital and Com Lab-isolated E. coli 
were 20% and 34%, respectively, and those of K. pneumoni-
ae were 33% and 44%, respectively (Table 2, footnote).
The resistance rates of hospital-isolated Enterobacter clo-
acae and S. marcescens were 32% and 14% to ceftazidime, 
11% and 13% to cefepime, 5% and 10% to amikacin, and 
11% and 16% to fluoroquinolone. The resistance rates of 
hospital-isolated S. maltophilia were 46% to ceftazidime, 
9% to fluoroquinolone, and 12% to cotrimoxazole. The re-
sistance rates of Acinetobacter spp. isolated by hospitals 
and Com Labs were 57% and 47% to ampicillin-sulbactam, 
64% and 66% to cefepime, 51% and 48% to imipenem, 48% 
and 25% to amikacin, 67% and 71% to fluoroquinolone, re-
spectively. The resistance rates of P. aeruginosa isolated by 
hospitals and Com Labs were 23% and 34% to ceftazidime, 
among the Com Lab isolates. As in the 2007 study,11 the re-
sistance rates did not include intermediate susceptibility, 
and the mean resistance rates were calculated by averaging 
the resistance rate at each hospital to avoid the influence of 
large numbers of isolates at large hospitals. If a hospital 
tested less than ten isolates of an organism, they were exclud-
ed from the analysis to avoid biasing the rates.15,16 Statistical 
significance of the differences in resistance rates was not de-
termined in this surveillance as it has been a common prac-
tice in large scale and continuous surveillance programs.17,18
RESULTS
 
Rank order of bacteria 
The total numbers of bacterial isolates tested in 2009 were: 
142,107 by 24 hospitals, and 68,391 by two Com Labs (Ta-
ble 1). The five most prevalent bacteria tested by the hospi-
tals were E. coli (21.1%), S. aureus (16.6%), coagulase-nega-
tive staphylococci (CNS, 13.8%), P. aeruginosa (9.7%), and 
K. pneumoniae (9.4%). The 6th to 8th most prevalent organ-
isms were E. faecalis (7.4%), Acinetobacter spp. (6.6%), and 
E. faecium (6.1%). The five most prevalent organisms test-
ed by the Com Lab were E. coli (26.8%), P. aeruginosa 
(18.1%), K. pneumoniae (11.7%), S. aureus (11.1%), and E. 
faecalis (7.4%). The 6th to 8th most prevalent organisms 
were CNS (7.3%), Acinetobacter spp. (5.7%), and Serratia 
marcescens (3.2%). 
Table 1. Number, Proportion, and Rank Order of Clinically Important Bacteria Isolated in 2007 and 2009 
Bacteria
Hospitals Commercial laboratories
No. (%) of isolates Rank order No. (%) of isolates Rank order
2009 2009 2007 2009 2009 2007
Escherichia coli   30,005 (21.1)   1   1 18,308 (26.8)   1   1
Klebsiella pneumoniae   13,343 (9.4)   5   5   7,997 (11.7)   3   4
Enterobacter cloacae     4,353 (3.1)   9   9   1,730 (2.5) 10   9
Serratia marcescens     2,142 (1.5) 12 10   2,208 (3.2)   8   7
Stenotrophomonas maltophilia     3,326 (2.3) 10 NT   1,567 (2.3) 11 NT
Acinetobacter spp.     9,426 (6.6)   7   8   3,899 (5.7)   7   6
Pseudomonas aeruginosa   13,755 (9.7)   4   4 12,404 (18.1)   2   2
Haemophilus influenzae        651 (0.5) 13 13        30 (0.04) 14 13
Non-typhoidal Salmonella        506 (0.4) 14 12      226 (0.3) 13 12
Staphylococcus aureus   23,578 (16.6)   2   2   7,567 (11.1)   4   3
Coag-Neg staphylococci   19,578 (13.8)   3   3   5,018 (7.3)   6   8
Enterococcus faecalis   10,516 (7.4)   6   6   5,038 (7.4)   5   5
E. faecium     8,641 (6.1)   8   7   1,895 (2.8)   9 10
Streptococcus pneumoniae     2,287 (1.6) 11 11      504 (0.7) 12 11
Total 142,107 (100) 68,391 (100)
Coag-Neg, coagulase negative; NT, not tested.  
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resistant to penicillin G at the CLSI meningitis breakpoint. 
Trends of resistance
MRSA, suspected penicillin G-nonsusceptible S. pneumoni-
ae by the oxacillin disk screening test for meningitis interpre-
tation, and ampicillin-resistant E. faecium have remained 
highly prevalent over the past 13 years (Fig. 1). The propor-
tion of vancomycin-resistant E. faecium gradually increased 
from 4% in 1997 to 29% in 2009. 
Among the Gram-negative bacilli tested, the resistance 
rates of K. pneumoniae to ceftazidime and cefoxitin gradu-
ally increased, reaching 33% and 25% in 2009, respective-
ly; the resistance rate to fluoroquinolone, on the other hand, 
increased rapidly from 8% in 1997 to 33% in 2009 (Fig. 2). 
The amikacin resistance rate of K. pneumoniae reached 
24% in 2005, then decreased to 15% in 2009. 
The high resistance rates of Acinetobacter spp. in 1999 to 
fluoroquinolone, amikacin, and ceftazidime decreased until 
2007, but the rates increased again in 2009 to 67%, 66%, and 
26% and 31% to imipenem, 19% and 37% to amikacin, 
and 39% and 53% to fluoroquinolone, respectively. 
The resistance rates of nontyphoidal Salmonella isolates 
from hospitals and Com Labs were 20% and 43% to ampi-
cillin, 14% and 6% to cefotaxime, and 1% and 0% to fluoro-
quinolone, respectively. Among 651 H. influenzae isolates 
from hospitals, 44% were resistant to ampicillin (Table 2, 
footnote). 
The resistance rates of Gram-positive cocci are shown in 
Table 3. The resistance rates to oxacillin (or to cefoxitin for 
MRSA detection), and clindamycin were: 69% and 60% 
among the hospital isolates, and 74% and 57% among the 
Com Lab isolates, respectively. The resistance rates of E. fae-
calis hospital isolates to ampicillin and vancomycin were 6% 
and 0.7%, respectively, but those of E. faecium were 92% 
and 29%, respectively. The resistance rates of E. faecium 
Com Lab isolates to ampicillin and vancomycin were 86% 
and 24%, respectively. Among the S. pneumoniae strains, 
39% of hospital isolates and 44% of Com Lab isolates were 
Table 2. Antimicrobial Resistance of Clinically Important Gram-Negative Bacilli Isolated at Hospitals and at Commercial Labo-
ratories in 2009*
Antimicrobial   
  agents
Resistance (%) of isolates (hospital/commercial laboratory) 
E. coli
K. pneu- 
moniae
E. cloacae
S. marce- 
scens
Non-T 
Salmonella
S. maltophilia
Acineto- 
bacter spp.
P. aeru- 
ginosa
30,005/18,308† 13,343/7,997 4,353/1,730 2,142/2,208 506/226 3,326/1,567 9,426/3,899 13,755/12,404
Ampicillin 67/74 -‡ - - 20/43 - - -
Ampicillin-  
  sulbactam
30/11 51/42 - - - - 57/47 -
Cephalothin 29/38 40/53 - - - - - -
Cefotaxime 19/31 30/43 32/20 25/20 14/6 - 77/- 70/-
Ceftazidime 17/31 33/46 32/23 14/5 11/6    46/27 66/73 23/34
Cefepime 17/30 27/40 11/6 13/2 - - 64/66 24/38
Aztreonam 18/30 35/46 31/21 17/14 12/6 - 77/83 28/35
Cefoxitin   8/15 25/32 - - - - - -
Piperacillin 52/65   78/100 35/34 37/41 - - 65/74 30/45
Piperacillin-
  tazobactam
4/9 15/- 16/16 15/6 - - 55/68 24/43
Imipenem 0.1/0 0.5/0.5 0.6/0.5 1.3/0 - - 51/48 26/31
Meropenem 0.1/0 0.8/0.5 0.7/0.5 1.3/0 - - 56/60 23/36
Amikacin 2/4 15/26 5/5 10/19 - - 48/25 19/37
Gentamicin 26/34 19/28 13/14 25/38 - - 64/70 29/47
Tobramycin 18/20 27/38 18/21 33/44 - - 54/47 28/46
Fluoroquinolone 35/48 33/39 11/11 16/19   1/0    9/5 67/71 39/53
Cotrimoxazole 36/- 18/-  23/- 19/-  9/- 12/- 67/- -
Tetracycline 48/51 20/20 21/18 45/32  5/-    8/2 59/50 -
Non-T, non-typhoidal.
*Data not shown in the table: ESBL-positive rates of E. coli 20% and 34%, and K. pneumoniae 33% and 44% for hospitals and commercial laboratories 
isolates; ampicillin-resistance rates of H. influenzae 44% among 651 isolates at hospitals, and 63% among 30 isolates at commercial laboratories.
†Number of isolates from hospitals/commercial laboratories.
‡not tested. 
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imipenem-resistant P. aeruginosa, oxacillin-resistant S. au-
reus, and vancomycin-resistant E. faecium were more preva-
lent among ICU isolates than among non-ICU isolates (Fig. 
5). It was observed that the imipenem resistance rate of P. 
aeruginosa ICU isolates was almost two-fold higher (39%) 
than that of the non-ICU isolates (20%). 
The proportions of antimicrobial-organism combinations 
detected by a Com Lab from hospital patients and from clinic 
patients are shown in Fig. 6. The isolates from hospital patients 
showed a 3-fold higher rate of ceftazidime-resistant E. coli, 
more than 2-fold higher rates of ceftazidime-resistant K. pneu-
moniae, and imipenem-resistant Acinetobacter spp., and a 
nearly 2-fold higher rate of imipenem-resistant P. aeruginosa. 
48%, respectively (Fig. 3). The proportion of imipenem-re-
sistant isolates steadily increased from 1% in 1997 to 22% 
in 2007, and then drastically increased, reaching 51% in 
2009. The high fluoroquinolone resistance rates of P. aeru-
ginosa fluctuated between 33% and 42% during the period 
of 1997-2009, while the amikacin resistance rates steadily 
declined from 33% in 1997 to 19% in 2009 (Fig. 4). The cef-
tazidime and imipenem resistance rates slowly increased 
from 16% to 23% and from 17% to 26%, during the study 
period, respectively. 
Analysis of the data from six hospitals with >1,000 beds 
showed that cefotaxime-resistant E. coli, ceftazidime-resis-
tant K. pneumoniae, imipenem-resistant Acinetobacter spp., 
Table 3. Antimicrobial Resistance of Clinically Important Gram-Positive Cocci Isolated at Hospitals and in 
Commercial Laboratories in 2009
Antimicrobial agents
Resistance (%) of isolates (hospital/commercial laboratory)
S. aureus*
Coag-Neg 
Staphylococcus* 
E. faecalis E. faecium S. pneumoniae
23,578/7,567 19,578/5,018 10,516/5,038 8,641/1,895 2,287/504
Penicillin/ampicillin† 94/97 89/94 6/- 92/86    39/44
Gentamicin 56/58 47/33 - -   -
Ciprofloxacin 57/54 44/37 30/37 91/88    6/6
Clindamycin 60/57 49/34 - - 60/-
Erythromycin 67/64 60/52 72/74 96/86   70/73
Fusidic acid 49/36 42/57 - -    -
Oxacillin/cefoxitin 69/74 73/74 - - 70/-
Tetracycline 55/58 31/31 85/87 22/22   69/73
Teicoplanin 0.1/0 1.3/0 0.9/1 22/14   -
Vancomycin 0/0 0.02/0 0.7/2 29/24   -
Coag-Neg, coagulase-negative; -, not tested.
*4% and 32% of hospital-isolated S. aureus and Coag-Neg Staphylococcus, respectively, were resistant to cotrimoxazole.
†Penicillin for Staphylococcus spp., and S. pneumoniae, and ampicillin for Enterococcus spp.
Fig. 1. Resistance trends of gram-positive cocci isolated in 1997-
2009 from the participating hospitals. Oxacillin-resistant S. aureus 
(OXA-R SAU), penicillin G-nonsusceptible S. pneumoniae (PEN-
NS SPN), and ampicillin-resistant E. faecium (AMP-R EFM) re-
mained highly prevalent. However, the proportion of vancomycin-
resistant E. faecium (VAN-R EFM) gradually increased from 4% in 
1997 to 29% in 2009.
Fig. 2. The resistance trends of K. pneumoniae isolated in 1997-2009 
from the participating hospitals. The resistance rates to ceftazidime 
(CAZ-R), cefoxitin (FOX-R) gradually increased and reached 33% 
and 25%, respectively, in 2009, whereas the resistance rate to fluo-
roquinolone (FQN-R) increased rapidly from 8% in 1997 to 33% in 
2009. The amikacin resistance rate (AMK-R) increased to 24% in 
2005 and then decreased to 15% in 2009.
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laboratory or by analyzing the susceptibility data generated 
by each hospital laboratory. It was considered that the pres-
ent need is for a supranational resistance surveillance system 
including non-invasive isolates, preferably based on all rou-
tine susceptibility data obtained from local laboratories.19 
The present KONSAR study showed that the majority of 
hospital laboratories used commercial broth microdilution 
methods for susceptibility testing of E. coli and S. aureus, 
which can represent Gram-negative and Gram-positive bac-
teria, respectively. Automation and rapid results are some of 
the advantage of these methods, but they may not perform 
optimally for the detection of some antimicrobial-organism 
DISCUSSION
   
The prevalence of resistant organisms varies significantly by 
time, country, and patient population. Therefore, antimicro-
bial resistance surveillance studies are very important to 
monitor levels of endemic or emerging resistance. In fact, 
with rapid increases in resistant bacteria, we need to devote 
more surveillance efforts to help delay the increasing trend 
of resistance, although it is impossible to completely over-
come the problem. An antimicrobial surveillance study is 
done either by testing collected isolates at a coordinating 
Fig. 3. The resistance trends of Acinetobacter spp. isolated in 1997-
2009 from the participating hospitals. The high resistance rates in 
1999 to fluoroquinolone (FQN-R), amikacin (AMK-R), and ceftazi-
dime (CAZ-R) decreased by 2007, but the rates increased again in 
2009 to 67%, 66%, and 48%, respectively. The proportion of imipen-
em-resistant (IPM-R) isolates steadily increased from 1% in 1997 to 
22% in 2007, and after that the increase was drastic, reaching 51% 
in 2009.
Fig. 4. The resistance trends of P. aeruginosa isolated in 1997-2009 
from the participating hospitals. The high fluoroquinolone (FQN-R) 
resistance rates fluctuated between 33% and 42% during the study 
period. The amikacin resistance rate (AMK-R) declined steadily 
from 33% in 1997 to 19% in 2009. The resistance rates to ceftazi-
dime (CAZ-R) and imipenem (IPM-R) increased slowly from 16% to 
23% and from 17% to 26%, respectively, during the study period. 
Fig. 5. Comparison of resistance rates of ICU vs. non-ICU isolates 
from six hospitals with >1,000 beds. Cefotaxime-resistant E. coli 
(CTX-R ECO), ceftazidime-resistant K. pneumoniae (CAZ-R KPN), imi-
penem-resistant Acinetobacter spp. (IPM-R ACI), imipenem-resistant 
P. aeruginosa (IPM-R PAE), oxacillin-resistant S. aureus (OXA-R 
SAU), and vancomycin-resistant E. faecium (VAN-R EFM) were 
much more prevalent among ICU isolates than among non-ICU iso-
lates. The imipenem-resistance rate of P. aeruginosa ICU isolates 
was almost two-fold higher (39%) than that of non-ICU isolates (20%).
Fig. 6. The high prevalence of four antimicrobial agent-organism 
combinations among commercial laboratory tested isolates from 
hospital patients compared to those from clinic patients. The isolates 
from hospital patients showed a 3-fold higher rate of ceftazidime-re-
sistant (CAZ-R) E. coli, more than 2-fold higher rates of CAZ-R K. 
pneumoniae and imipenem-resistant (IPM-R) Acinetobacter spp., 
and nearly 2-fold higher rate of IPM-R P. aeruginosa. All numbers of 
isolates are shown in the bars, and the proportions (%) of antimicro-
bial-organism combinations are shown on the bars.  
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was 3.3% and rank order was No. 8.22 In our study, the rank 
order of S. maltophilia was similar, i.e., No. 10.
Our present Com Lab data showed that isolates from sec-
ondary-care hospitals were much more frequently resistant 
than those from primary-care clinics, suggesting a higher 
prevalence of nosocomially acquired pathogens among the 
hospital isolates (Fig. 6). In Germany, hospitals with their 
own microbiology laboratory reported higher frequencies 
of health care-associated infections than did hospitals with-
out in-house laboratory services.23 
In a recent review, Peleg and Hooper24 expressed concern 
about hospital-acquired Gram-negative bacterial infections. 
In the U.S., it was estimated that a total of 1.7 million hospi-
tal-acquired infections occurred (4.5 per 100 admissions) in 
2002, and hospital-acquired infections were the sixth leading 
cause of death. It is of great concern that only approximately 
one third of hospital-acquired infections are preventable. 
ICUs are reservoirs of resistant bacteria. The U.S. Na-
tional Healthcare Safety Network (NHSN) indicated that 
Gram-negative bacteria caused more than 30% of hospital-
acquired infections, and these bacteria predominated in cas-
es of ventilator-associated pneumonia (47%) and urinary 
tract infections (45%). In ICUs, Gram-negative bacteria ac-
counted for about 70% of these types of infections.24 An in-
ternational study showed that resistance rates of ICU iso-
lates from Latin America, Asia, Africa, and Europe were 
higher than those in the U.S.: MRSA 84.1% vs. 56.8%, K. 
pneumoniae to ceftazidime or ceftriaxone 76.1% vs. 27.1%, 
A. baumannii to imipenem 46.3% vs. 29.2%, and P. aerugi-
nosa to piperacillin 78.0% vs. 20.2%, respectively.25 Howev-
er, it is noteworthy that in the U.S., the proportion of MRSA 
was high, and those of other organisms were not low. 
Resistance is reported to have increased throughout Eu-
rope, among Gram-negative bacilli in particular.19 Gram-
negative bacterial infections have features that are of partic-
ular concern. These organisms are highly efficient at up-
regulating or acquiring resistance genes.24 In our present 
study, the ceftazidime resistance rate of hospital isolates of 
K. pneumoniae was 33%. The rate was much higher than 
the 0% among 27 isolates in Iceland, but much lower than 
the 68.7% found in Greece (www.ecdc.europa.eu). Among 
the Gram-negative bacilli associated with intra-abdominal 
infections in 2008 from 11 Asia-Pacific countries, the high-
est rates of ESBL-producing E. coli and K. pneumoniae 
were observed in India (61.2% and 46.8%, respectively); 
the rates were 30.4% and 25.0% in Korea, respectively.1
Currently the most feared resistance is those to carbapen-
combinations. With the increasing prevalence of multidrug 
resistant (MDR) Acinetobacter spp. and P. aeruginosa, poly-
myxins and tigecycline susceptibility testing have become a 
requirement, but these were not included in the present 
study mainly because of their unavailability in the majority 
of commercial systems. 
In 2010, the CLSI13 lowered the resistance breakpoints of 
cefotaxime, ceftazidime, and aztreonam to ≥4 μg/mL, ≥16 
μg/mL, and ≥16 μg/mL, respectively, and eliminated the 
necessity of ESBL testing of E. coli, K. pneumoniae spp., 
and P. mirabilis. In our present study, the previous CLSI 
breakpoints12 were used for these antimicrobial agents, and 
some laboratories differentiated ESBL-producing isolates.  
In the analysis of laboratory generated susceptibility data, 
the CLSI20 recommends including only the first isolate if 
there were multiple isolates from one patient, for the pur-
pose of guiding clinicians in the empirical selection of ap-
propriate antimicrobial agents. The WHONET software14 
can be used to exclude duplicate isolates. In the present 
study, the Com Labs were not able to exclude duplicate iso-
lates due to difficulty identifying relevant patients. This ap-
parently raised the resistance rates of some organisms to 
certain antimicrobial agents. However, if only the first iso-
late is included, and particularly if the analysis is made only 
once a year, it may underestimate resistance acquired dur-
ing hospitalization, as well as the emergence of resistance 
due to mutations during therapy.19 A study showed that not 
all U.S. hospitals excluded duplicate isolates.21 In fact, to 
detect developing resistance during therapy, the CLSI13 rec-
ommends testing the susceptibility of subsequent isolates 
three to four days after the initial isolation of Enterobacter, 
Citrobacter, and Serratia spp. to third-generation cephalo-
sporins, of P. aeruginosa to all antimicrobial agents and of 
staphylococci to quinolones. 
In 2009, as in 2007, E. coli, S. aureus, CNS, P. aerugino-
sa, and K. pneumoniae were the five most prevalent organ-
isms among those isolated by hospitals (Table 1). Among 
the Com Lab isolates, E. coli, P. aeruginosa, and E. faeci-
um were ranked numbers 1, 2, and 5, respectively, in both 
2007 and 2009, but the rank orders of S. aureus and K. pneu-
moniae were reversed (3 and 4 in 2007; 4 and 3 in 2009, re-
spectively). The rank orders in the U.S. were largely simi-
lar. The SENTRY Program in 2004-2008 showed that the 
five most frequently isolated bacteria from hospitalized pa-
tients with pneumonia were S. aureus (36.3%), P. aerugino-
sa (19.7%), Klebsiella spp. (8.5%), E. coli (4.6%) and Aci-
netobacter spp. (4.8%). The proportion of S. maltophilia 
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and ventilator-associated bacterial pneumonia in North 
America, 54% were nonsusceptible to oxacillin.22 Vancomy-
cin-resistant enterococci are also important Gram-positive 
nosocomial pathogens. In the U.S., hospitalizations with van-
comycin-resistant enterococcal infections increased from 
3.16 to 6.51 per 10,000 hospitalizations during 2003-2006.32 
The U.S. NHSN data33 showed that 80% of E. faecium iso-
lates in 2006 and 2007 from central line-associated blood-
stream infections, catheter-associated urinary tract infections, 
ventilator-associated pneumonia, and surgical site infections 
were vancomycin resistant. 
The EARS-Net 2009 report (www.ecdc.europa.eu) showed 
that the prevalence of invasive MRSA and vancomycin-resis-
tant E. faecium varied greatly by country. For example, the 
proportions of MRSA were 0% of 59 isolates in Iceland, and 
49.1% of 1,824 isolates in Portugal, and those of vancomycin-
resistant E. faecium were 0% of 243 isolates in Finland, and 
37.8% of 386 isolates in Ireland. The report also showed that 
the resistance rates varied greatly depending on hospitals even 
within a country: the mean prevalence of MRSA from Ger-
many was 18.7%, but ranged from a minimum of 0% to a 
maximum of 60%. In our present study, 39% of hospital iso-
lates of S. pneumoniae were resistant to penicillin G at the 
CLSI meningitis breakpoint.13 This rate did not differ greatly 
from those of a U.S. study, 28.4% in 1998 and 41.0% in 
2009.34 Until 2008, penicillin G susceptibility of all S. pneu-
moniae isolates was interpreted according to CLSI breakpoint 
for meningitis, because a non-meningitis breakpoint did not 
exist. In our present report, we continued to include oxacillin 
screening test results for respiratory isolates, because the ma-
jority of S. pneumoniae serotypes recovered from the respira-
tory tract are those causing meningeal infections, too, and be-
cause the result could show a resistance trend. 
With increasing international air travel and import of ani-
mal produce, it has become very difficult to control the 
spread of antimicrobial-resistant bacteria. Carbapenemases 
IMP-1 and VIM-2, initially detected in Japan35 and in 
France,7 respectively, are now widespread globally, including 
in Korea. Scandinavia is a region with a low prevalence of 
antimicrobial resistance, but import and local clonal expan-
sion of VIM-2-producing P. aeruginosa has been reported.2 
Also, blaSPM-1, which was initially found in Brazil, was de-
tected recently in a P. aeruginosa isolate in Switzerland.36 An 
isolate of K. pneumoniae, producing a new MBL, NDM-1, 
was first found in Sweden in a patient transferred from In-
dia.8 K. pneumoniae isolates producing a class A carbapene-
mase, KPC-2, were first found in New York.6 K. pneumoniae 
ems. In our present study, 26% of P. aeruginosa were resistant 
to imipenem (Table 2, Fig. 4). This rate is much higher than 
the 0% of 16 isolates found in Iceland, but much lower than 
the 44% found in Greece (www.ecdc.europa.eu). Of over 800 
β-lactamases identified from Gram-negative bacilli, at least 
120 have been detected in P. aeruginosa. IMP- and VIM-type 
MBLs are predominantly found in P. aeruginosa and in Aci-
netobacter spp.26 The proportions of imipenem-resistant iso-
lates in the 1997 vs. 2009 KONSAR studies were: P. aerugi-
nosa 17% vs. 26%, and Acinetobacter spp. 1% vs. 51%, 
respectively (Figs. 3 and 4). The drastic increase in imipenem-
resistant Acinetobacter spp. was probably due to OXA-type 
carbapenemase production. It is interesting that almost all car-
bapenem-resistant A. baumannii carried blaOXA-23-like or ISA-
ba1-activated blaOXA-51-like genes, while the majority of non-
baumannii Acinetobacter carried MBL genes.27 
The terms MDR, extreme drug resistance (XDR), and 
pandrug resistance (PDR), are very useful to attract atten-
tion, but there has been no consensus as to their definition. 
The term PDR in A. baumannii and P. aeruginosa in partic-
ular is thought to have been used inappropriately.28 In one 
study, MDR was defined as nonsusceptibility to one or 
more antimicrobials in three or more antimicrobial classes 
(antipseudomonal penicillins, third-generation cephalospo-
rins, carbapenems, fluoroquinolones, and aminoglyco-
sides). The definition did not include colistin and tigecy-
cline susceptibility.29 The study showed that the proportions 
of MDR isolates of A. baumannii and P. aeruginosa report-
ed to the U.S. NHSN systems in 2008 were 74% and 17%, 
respectively, but XDR isolates (nonsusceptible to all anti-
microbials including polymyxins and tigecycline) remained 
rare. Of the 344 blaKPC-positive ICU isolates of Enterobac-
teriaceae, 91% and 99% were susceptible to colistin and ti-
gecycline, respectively. Only two isolates were nonsuscepti-
ble to both antimicrobial agents. In Korea, colistin-resistant 
A. baumannii isolates were detected.30 Therefore, it is nec-
essary to include colistin and tigecycline susceptibility in 
future surveillance studies in Korea. 
In our present study, 44% of hospital isolates of H. influ-
enzae were resistant to ampicillin. Bae, et al.31 reported that 
among 544 nationwide collections of respiratory isolates of 
H. influenzae, 58.5% were ampicillin resistant, and 52.4% 
were β-lactamase producers.
In Korea, hospital-associated MRSA has been a serious 
problem (Fig. 1). MRSA has become a problem organism in 
North America as well. The SENTRY Program showed that 
among the S. aureus isolates in 2008 from hospital-acquired 
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